Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

Phase 2

Completed

Conditions: Osteoporosis
Osteopenia

Interventions: Drug: BPS804 20mg/Kg
Drug: Placebo to 20mg/Kg BPS804

Registration Number: NCT01406548

Lead Sponsor: Ultragenyx Pharmaceutical Inc

Brief Summary: This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens. This information will permit a comparison of the possible risks and benefits of different dosing regimens of the study drug to enable optimal doses and dose intervals to be tested in subsequent studies.

Detailed Description: This study was conducted and previously posted by Novartis. The record was transferred to Ultragenyx in February 2021.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 44

Inclusion Criteria

Postmenopausal women (natural or surgically induced menopause)
Low bone mineral density (BMD), as defined by a T score or equivalent BMD absolute value (g/cm2) for lumbar spine of between -2.0 and -3.5, inclusive
Body mass index (BMI) must be within the range of 18 to 35kg/m2. Subjects must weigh between 45 and 120kg inclusive to participate.
25-(OH) vitamin D serum level of ≥ 15ng/ml
Serum calcium within normal limits

Exclusion Criteria

Subjects with suspected neural foraminal stenosis (e.g., cervical, spinal, lumbar), or history of Bell's palsy, cranial nerve disorders, temporomandibular joint and muscle disorders.
Subjects who have an increased baseline risk of osteosarcoma: Paget's disease of the bone or unexplained and clinically significant elevations of alkaline phosphatase and/or subjects who have received radiation therapy involving the skeleton.
Subjects with any known bone diseases other than postmenopausal osteoporosis.
Subjects with a history of an osteoporotic fracture (e.g., vertebral fracture, fragility fracture of the wrist, radius, humerus, hip, or pelvis).
Subjects who are regularly using or have regularly used agents affecting bone metabolism:
- Calcitonin, estrogen, SERMs (raloxifene, Tamoxifen, etc.), Tibolone progestin, or androgens within the last three (3) months prior to screening.
- Any oral bisphosphonate, lithium chloride, fluoride or systemic glucocorticosteroids (p.o. or i.v.) where the total dose exceeds 750 mg of prednisone or equivalent within the last year prior to screening.
- Any previous use of denusomab (ProliaTM), parathyroid hormone (ForteoTM), and/or PTH analogs, strontium ranelate, or parenteral formulations of bisphosphonates.
Current disease(s) known to influence calcium metabolism including hyperparathyroidism, hypoparathyroidism, hypocalcemia or hypercalcemia.
Any disease, abnormality or deformation of the spine (e.g., scoliosis, ankylosing spondylitis, osteophytes) or hip (e.g., joint prosthesis) which would preclude the proper acquisition of a lumbar spine DXA (L1-L4) or femur DXA, respectively.

Other protocol-defined inclusion/exclusion criteria may apply

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BPS804 dosing frequency 1	BPS804 20mg/Kg	Subjects dosed 20mg/Kg BPS804 monthly
placebo dosing frequency 2	Placebo to 20mg/Kg BPS804	Subjects dosed with matching placebo to 20mg/Kg BPS804 every 3 months
BPS804 dosing frequency 3	BPS804 20mg/Kg	Subjects dosed with 20mg/Kg BPS804 weekly
BPS804 dosing frequency 2	BPS804 20mg/Kg	Subjects dosed with 20mg/Kg BPS804 quarterly
placebo dosing frequency 1	Placebo to 20mg/Kg BPS804	Subjects dosed with matching placebo to 20mg/Kg BPS804 monthly
Placebo dosing frequency 3	Placebo to 20mg/Kg BPS804	Subjects dosed with matching placebo to 20mg/Kg BPS804 weekly

Primary Outcome Measures

Name	Time	Method
Change from baseline to month 9 in bone mineral density at the lumbar spine for the individual BPS804 groups and pooled placebo arms.	9 months
The number (percent) of subjects experiencing adverse events or serious adverse events	9 months

Secondary Outcome Measures

Name	Time	Method
Characterization of the PK profile of BPS804: time to reach the maximum Characterization of the PK profile of BPS804: maximum plasma concentration (Cmax)	260 days
Change from baseline during 9 months of serological bone biomarkers for the individual BPS804 groups and pooled placebo arms.	9 months
Characterization of the PK profile of BPS804: area under the plasma concentration-time curve (AUC)	260 days
Characterization of the PK profile: time to reach the maximum concentration (Tmax)	260 days
Characterization of the PK profile of BPS804: half-life (T1/2)	260 days